Navigation Links
Review of probiotic trial research finds only Bifantis able to claim efficacy for IBS symptoms
Date:3/23/2009

eland in partnership with P&G, has been independently tested and evaluated in several clinical trials conducted with humans. This latest review provides continued clinical evidence of Bifantis efficacy in helping to manage a range of gastrointestinal issues including abdominal pain, bloating, constipation, diarrhea, gas and urgency. Bifantis efficacy data has been published or referenced in several medical journals, including the American Journal of Gastroenterology2 , Gastroenterology3 , New England Journal of Medicine4 , Public Library of Science (PLoS)5 and Nutrition in Clinical Practice6. Bifantis is found in the number one gastroenterologist recommended probiotic supplement in the United States7 .

Susan Abeln, Principal Scientist at Procter & Gamble said, "P&G has worked with Alimentary Health to study and develop a supplement with Bifantis because we firmly believe in the benefits of this strain for the millions of Americans struggling to manage digestive upsets each day. We're excited to make Bifantis available to consumers nationwide this spring."

Further credentialing the probiotic strain, P&G recently announced that Bifantis meets the probiotic guidelines established by The International Scientific Association for Probiotics and Prebiotics (ISAPP). These guidelines include five key criteria that consumers should consider when selecting a probiotic product - strain specificity, clinical proof, packaging, and the quality and quantity of probiotics in a product. Bifantis is proven to fully meet these guidelines, making it a good option for those who want to build and maintain a natural defense against abdominal discomfort and episodic digestive upsets such as constipation, diarrhea, urgency, gas and bloating.


'/>"/>

Contact: Chido Tsemunhu
Chido.Tsemunhu@mslworldwide.com
212-468-3681
Manning Selvage & Lee
Source:Eurekalert

Page: 1 2

Related biology news :

1. Stanford researchers publish review of US medical device regulation
2. Medicines derived from cannabis: a review of adverse events
3. Review article provides tools for the Rosaceae genomics community
4. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
5. Experts discuss applying systematic review to the field of nutrition
6. Biophysical Reviews makes debut in 2009
7. A re-review of peer review: Leading journal looks to end the review nightmare
8. Swedish university honors probiotics scientist
9. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
10. Vitamin E trials fatally flawed
11. Research team says extraterrestrial impact to blame for Ice Age extinctions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... With land degradation in dryland regions continuing to ... agreed on scientist-recommended indicators for monitoring and assessing ... The landmark agreement was reached after two weeks ... ministers attending the Ninth Session of the Conference ...
... October 7, 2009 H2 Blocker drugs, such as Famotidine, ... (heartburn), pose no significant risks for the fetus according to ... of the Negev. The study published in the ... safety of the fetus when H2 blocker drugs are ...
... look for clues about therapies and cures for life-threatening ... logical to do so. But the decision as to ... provides a unique ethical conundrum, says a Tel Aviv ... journal Science , co-authored by colleagues from The ...
Cached Biology News:Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers 2Keeping DNA 'all in the family' 2Keeping DNA 'all in the family' 3
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... 2010 , - Proposed recommended cash acquisition of specialty gastrointestinal, ... equity purchase price of, EUR428 million in cash. ... date, Movetis held EUR100 million in cash; based on this the, ... - Strong strategic fit with Shire,s growing core GI business; ...
... innovation that can help scientists observe a reaction moving at ... spatial resolution, is a feat some would say is nearly ... scientists who developed the dynamic transmission electron microscope (DTEM). ... of scientific phenomena while it,s happening has earned it one ...
... EAST NORRITON, Pa. , Aug. 2 Tengion Inc. (Nasdaq: ... A. Brian Davis to the position of Chief Financial Officer. ... a biopharmaceutical company using enzymatic technologies to develop improved protein therapeutics. At ... personnel at three sites.  , , ...
Cached Biology Technology:Shire Proposes to Expand Specialist Gastrointestinal Portfolio 2Shire Proposes to Expand Specialist Gastrointestinal Portfolio 3Shire Proposes to Expand Specialist Gastrointestinal Portfolio 4Shire Proposes to Expand Specialist Gastrointestinal Portfolio 5Shire Proposes to Expand Specialist Gastrointestinal Portfolio 6Shire Proposes to Expand Specialist Gastrointestinal Portfolio 7Shire Proposes to Expand Specialist Gastrointestinal Portfolio 8Shire Proposes to Expand Specialist Gastrointestinal Portfolio 9Livermore's DTEM earns innovation award from Microscopy Today 2Tengion Appoints A. Brian Davis Chief Financial Officer 2
ID clarifier: platform...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
... Tetrad 2 thermal cycler accommodates a ... heat-pump assemblies), which hold different types ... computer drives an advanced graphical interface ... lid temperatures. Peltier heat pumps, built ...
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
Biology Products: